Workflow
Cariboo Rose Resources Announces Upsize of Private Placement
Thenewswire· 2026-04-28 21:00
Vancouver, BC – TheNewswire - April 28, 2026 – Cariboo Rose Resources Ltd. (TSX-V: CRB) ("Cariboo Rose" or the "Company ") announces that it intends to the increase the proceeds from its unit private placement from $500,000 to $700,000 subject to regulatory acceptance. Proceeds from its flow-through share private placement will not change. The non-brokered private placements (the "Placement") will now consist of: The Placement will be non-brokered; however, the Company may pay finder's fees in accordance wi ...
United Arab Emirates Leaves OPEC In Favor Of ‘National Interest'
Forbes· 2026-04-28 21:00
Topline Tankers are seen at the Khor Fakkan Container Terminal in United Arab Emirates on June 23, 2025. AFP via Getty Images The United Arab Emirates has announced it will no longer be a member of the Organization of the Petroleum Exporting Countries, OPEC, starting May 1 after reflecting on its "long-term strategic and economic vision," a move that could impact the group's ability to control the supply of oil and prices around the world. ...
Granada Gold Mine Demonstrates 2.7x Grade Uplift on Open-Pit Mineralization through Ore Sorting at Saskatchewan Research Council
Thenewswire· 2026-04-28 21:00
XRT Sorting Upgrades 2.93 g/t Feed to 7.87 g/t at 88 Percent Gold Recovery — Two-Thirds of Mill Feed Rejected as Waste Before Processing Rouyn Noranda, Q.C. - TheNewswire - April 28, 2026 - Granada Gold Mine Inc. (TSXV: GGM) (OTC: GBBFF) (Frankfurt: B6D) (the "Company" or "Granada") is pleased to report results from an independent ore- sorting test program completed at the Saskatchewan Research Council ("SRC") that demonstrates a 2.7x gold- grade uplift on open-pit mineralization from the Granada deposit. A ...
Tesla's Down 16% This Year But Analysts See Upside With a $420 Price Target
247Wallst· 2026-04-28 20:59
核心观点 - 特斯拉第一季度业绩超出预期,汽车毛利率和自由现金流显著改善,但股价因市场对其高额研发投入和自动驾驶、机器人业务商业化时间线的担忧而承压[1][4][6] - 尽管股价年内下跌,多数分析师仍给予“持有”或更好评级,平均目标价420美元,较当前股价有约11.3%的上涨空间,看涨逻辑取决于其自动驾驶和机器人业务能否成功货币化[1][4][9] 财务业绩与运营表现 - 第一季度非GAAP每股收益为0.41美元,超出市场预期14.14%[1][6] - 第一季度营收为223.9亿美元,同比增长15.78%[6] - 汽车毛利率从16.2%扩大至21.1%[1][6] - 自由现金流同比飙升117.47%[1][6] - 股价在财报发布后收跌3.56%,并持续下跌,年内累计下跌16%[1][4][6] 未来增长驱动力与业务进展 - 全自动驾驶(FSD)活跃订阅数达128万,同比增长51%[2][7] - 4月已在达拉斯和休斯顿推出无人监督的Robotaxi服务,并计划扩展至菲尼克斯、迈阿密和拉斯维加斯[2][7] - Cybercab、Tesla Semi和Megapack 3均目标在2026年实现量产[7] - 正在弗里蒙特工厂安装Optimus人形机器人生产线,设计产能为每年100万台[2][8] 分析师观点与估值 - 覆盖特斯拉的48位分析师中,5位给予“强力买入”,18位给予“买入”,17位给予“持有”,6位给予“卖出”,2位给予“强力卖出”[9] - 分析师平均目标价为420美元,意味着较当前股价376.30美元有约11.3%的上涨潜力[4][9] - 公司当前市盈率(TTM)为345倍,前瞻市盈率为179倍[9] 市场关注与潜在挑战 - 投资者关注点转向不断上升的支出,以及自动驾驶和机器人领域的重大投资能否及时产生回报以支撑当前估值[4] - 公司季度研发支出达19.5亿美元[11] - 预测市场对商业化时间线持怀疑态度,Polymarket数据显示,市场认为特斯拉在6月30日前在加州推出Robotaxi的概率仅为13.5%,在年底前发布Optimus的概率为17%[2][11]
LPL Financial Welcomes Advisor Greg Selg
Globenewswire· 2026-04-28 20:55
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that Greg Selg, MBA, has joined LPL Financial's broker-dealer and Registered Investment Advisor (RIA) platform. Selg reported serving approximately $260 million in advisory, brokerage and retirement plan assets* and joins LPL from Osaic. Based in Bohemia, N.Y., on Long Island, Selg is the founder of G.S. Wealth Management and brings 25 years of industry experience serving individuals, families and small business owners. His clie ...
Inspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University
Globenewswire· 2026-04-28 20:51
RA'ANANA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IIINNW) ("Inspira" or the "Company"), today announced that it has received a $390,000 payment for an additive manufacturing electronics ("AME") system purchase order, which also establishes an ongoing recurring revenue stream, from a premier technological research university in the Asia-Pacific region, widely recognized for its leading advancements in quantum computing and quantum information networks. T ...
Sanmina: Market Finally Realizes Growth Potential (Rating Downgrade)
Seeking Alpha· 2026-04-28 20:45
Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...
欧莱雅中国一季度业绩加速领跑市场 多维度加码投资中国
证券日报网· 2026-04-28 20:45
本报记者 梁傲男 4月27日下午,"大美泱泱,智敬未来"欧莱雅中国2025/2026年度发展战略沟通会在上海举办。会上,欧莱雅中国宣布了两 项最新项目进展:与华山医院皮肤科合作开发的首项成果,理肤泉超分子控油平衡水乳系列全球重磅发布;携手中国妇女发展 基金会与中国科学院计算机网络信息中心,发起全新"一代耀一代"科技女生赋能计划,并将在五年内捐赠1000万元用于赋能科 学女性。 记者注意到,欧莱雅在此次沟通会上首次系统性地提出了"AI向美"的新理念,并将其作为贯穿全场、引领未来的核心思 考。正如欧莱雅北亚总裁及中国首席执行官博万尚所言:"步入AI驱动的新时代,美正以前所未有的方式连接科技与人文,重 塑产业格局,回应人们对美好生活的无限向往。我们坚信,美的未来正在中国创造。" 以消费者为中心锚定增长 面对这一新格局,欧莱雅中国副首席执行官及高档化妆品部总经理马晓宇肯定了行业的增长潜力,她围绕打造卓越品牌矩 阵、把握全品类机遇、提升全渠道体验、加强消费者共鸣四大维度分享了欧莱雅中国的战略洞察,阐释了以消费者为中心的破 局之道。 马晓宇对包括《证券日报》记者在内的媒体表示,欧莱雅将构建覆盖全品类、全价格阶梯的品牌布局 ...
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Globenewswire· 2026-04-28 20:45
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program Grand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the recent successful submission of a Clinical Trial Application (CTA) to G ...
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Globenewswire· 2026-04-28 20:45
Grand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the recent successful submission of a Clinical Trial Application (CTA) to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA (siRNA) product candidate, SIL204, in patients with locally advanced pancreatic cancer (LA ...